Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LAS VEGAS, May 28, 2013 /PRNewswire/ -- PharmaRoth Labs, Inc. (OTC Pink: ROTH) the exclusive producer, marketer & distributor of Sucanon®, an oral Type-II Diabetes treatment, announced today that it has entered into a definitive agreement with Marcas de Renombre, S.A de C.V. granting Marcas exclusive rights for the commercialization and distribution of Sucanon® in Mexico. The agreement is for 50 years with annual sales increases conditional for continuance of exclusivity, with the first shipment anticipated in June.
“We are very pleased to announce this agreement with Marcas de Renombre” said Luis Lopez, CEO of PharmaRoth. “We believe we have found a partner that is uniquely positioned to ensure market access and the commercial success of Sucanon®. This agreement is a major milestone for PharmaRoth, and a clear recognition of the demand Sucanon® brings.” MDR’s marketing strategy is a direct to Consumer Company with massive advertising through most media channels.
About Sucanon®
Sucanon® is approved as an OTC treatment for Type-II diabetes by regulatory authorities in Mexico, containing natural ingredient. It is one of only three approved drugs in the multi-billion dollar market for a class of diabetic medications called “insulin sensitizers”. Pre-clinical and clinical studies conducted ex-US have shown that Sucanon® and other insulin sensitizers lower a patient’s blood sugar by increasing the muscle, fat and liver’s sensitivity to the body’s own naturally produced insulin.
For further information regarding Sucanon®, please visit PharmaRoth Labs, Inc. website at http://pharmaroth.com/
About PharmaRoth Labs Inc.
PharmaRoth Labs, Inc. (OTCPink: ROTH) is focused on diabetes prevention and treatments. The Company holds the intellectual property and all exclusive world-wide rights related to the production, marketing, and distribution of Sucanon®, an oral treatment for Type-II diabetes. Sucanon® is a member of a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver’s sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars. PharmaRoth’s strategy is to increase awareness, acceptance, and distribution of Sucanon® globally.
About Marcas de Renombre S.A. de C.V.
Marcas de Renombre is established as company that develops and distributes several brands in different areas as skin cosmetics, personal care, and OTC. With more than 1,000 employees and growing annual sales, it is one of the largest advertisers in the Mexican Market.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact and Inquiries for Investor Relations:
Michael Irving
Paramount Advisors, LLC
407-878-5462
mike@parvise.com
SOURCE PharmaRoth Labs, Inc.
Help employers find you! Check out all the jobs and post your resume.
